Pages that link to "Q33355806"
Jump to navigation
Jump to search
The following pages link to High-resolution array copy number analyses for detection of deletion, gain, amplification and copy-neutral LOH in primary neuroblastoma tumors: four cases of homozygous deletions of the CDKN2A gene (Q33355806):
Displaying 48 items.
- Focal DNA copy number changes in neuroblastoma target MYCN regulated genes (Q28115604) (← links)
- Comprehensive SNP array study of frequently used neuroblastoma cell lines; copy neutral loss of heterozygosity is common in the cell lines but uncommon in primary tumors (Q31030415) (← links)
- Verification of genes differentially expressed in neuroblastoma tumours: a study of potential tumour suppressor genes (Q33494188) (← links)
- Research progress of neuroblastoma related gene variations (Q33566987) (← links)
- Array-based gene expression, CGH and tissue data defines a 12q24 gain in neuroblastic tumors with prognostic implication (Q33571656) (← links)
- High-risk neuroblastoma tumors with 11q-deletion display a poor prognostic, chromosome instability phenotype with later onset (Q33732709) (← links)
- Identification of epigenetically regulated genes that predict patient outcome in neuroblastoma (Q33818726) (← links)
- Isolation of disseminated neuroblastoma cells from bone marrow aspirates for pretreatment risk assessment by array comparative genomic hybridization. (Q33870055) (← links)
- Genomic organization and evolution of double minutes/homogeneously staining regions with MYC amplification in human cancer (Q34044287) (← links)
- Tumor development, growth characteristics and spectrum of genetic aberrations in the TH-MYCN mouse model of neuroblastoma (Q34531771) (← links)
- Genetic instability and intratumoral heterogeneity in neuroblastoma with MYCN amplification plus 11q deletion (Q34558670) (← links)
- Age dependence of tumor genetics in unfavorable neuroblastoma: arrayCGH profiles of 34 consecutive cases, using a Swedish 25-year neuroblastoma cohort for validation (Q34711056) (← links)
- Genome-wide analysis of recurrent copy-number alterations and copy-neutral loss of heterozygosity in head and neck squamous cell carcinoma (Q34764447) (← links)
- Aneuploidy in neuroblastoma tumors is not associated with inactivating point mutations in the STAG2 gene (Q35006926) (← links)
- Sequential dosing in chemosensitization: targeting the PI3K/Akt/mTOR pathway in neuroblastoma (Q35082400) (← links)
- Genome-wide molecular characterization of central nervous system primitive neuroectodermal tumor and pineoblastoma (Q35133413) (← links)
- Genome-wide methylation profiling identifies novel methylated genes in neuroblastoma tumors (Q36838937) (← links)
- The microenvironment of human neuroblastoma supports the activation of tumor-associated T lymphocytes (Q36866183) (← links)
- Genetic mapping with multiple levels of phenotypic information reveals determinants of lymphocyte glucocorticoid sensitivity (Q37217063) (← links)
- Escape from p53-mediated tumor surveillance in neuroblastoma: switching off the p14(ARF)-MDM2-p53 axis. (Q37603053) (← links)
- The consequences of uniparental disomy and copy number neutral loss-of-heterozygosity during human development and cancer (Q37886251) (← links)
- Genetic stratification of neuroblastoma for treatment tailoring (Q37932545) (← links)
- The role of genetic and epigenetic alterations in neuroblastoma disease pathogenesis (Q38070334) (← links)
- Recent insights into the biology of neuroblastoma (Q38240010) (← links)
- Hereditary myopathy with early respiratory failure associated with a mutation in A-band titin (Q38325462) (← links)
- Advances in the translational genomics of neuroblastoma: From improving risk stratification and revealing novel biology to identifying actionable genomic alterations (Q38625880) (← links)
- Neuroblastoma in children: Update on clinicopathologic and genetic prognostic factors. (Q38702196) (← links)
- TRPM7 maintains progenitor-like features of neuroblastoma cells: implications for metastasis formation (Q38896647) (← links)
- Low p14ARF expression in neuroblastoma cells is associated with repressed histone mark status, and enforced expression induces growth arrest and apoptosis. (Q39205970) (← links)
- Integrated cytogenetic and high-resolution array CGH analysis of genomic alterations associated with MYCN amplification (Q39555406) (← links)
- Gene amplification as double minutes or homogeneously staining regions in solid tumors: origin and structure (Q39680216) (← links)
- Chromosome 3p microsatellite allelotyping in neuroblastoma: a report on the technical hurdles (Q39835099) (← links)
- Clinical evaluation of integrated panel testing by next-generation sequencing for somatic mutations in neuroblastomas with MYCN unamplification (Q41472684) (← links)
- A 6-gene signature identifies four molecular subgroups of neuroblastoma (Q41980747) (← links)
- The emerging molecular pathogenesis of neuroblastoma: implications for improved risk assessment and targeted therapy (Q42089520) (← links)
- p53, SKP2, and DKK3 as MYCN Target Genes and Their Potential Therapeutic Significance (Q42362115) (← links)
- Recurrent pre-existing and acquired DNA copy number alterations, including focal TERT gains, in neuroblastoma central nervous system metastases (Q46269827) (← links)
- Mutant allele specific imbalance in oncogenes with copy number alterations: Occurrence, mechanisms, and potential clinical implications. (Q47164988) (← links)
- Copy number defects of G1-cell cycle genes in neuroblastoma are frequent and correlate with high expression of E2F target genes and a poor prognosis (Q50267850) (← links)
- The neuroblastoma and ganglion components of nodular ganglioneuroblastoma are genetically similar: evidence against separate clonal origins. (Q53030381) (← links)
- Quantitative analysis of somatically-acquired and constitutive uniparental disomy in gastrointestinal cancers (Q57797233) (← links)
- Cyclin D1 is a direct transcriptional target of GATA3 in neuroblastoma tumor cells (Q58321451) (← links)
- Segmental chromosome aberrations converge on overexpression of mitotic spindle regulatory genes in high-risk neuroblastoma (Q60819945) (← links)
- Preclinical evaluation of the first intravenous small molecule MDM2 antagonist alone and in combination with temozolomide in neuroblastoma (Q64237646) (← links)
- Low Frequency ALK Hotspots Mutations In Neuroblastoma Tumours Detected By Ultra-deep Sequencing: Implications For ALK Inhibitor Treatment (Q64252659) (← links)
- The genetic and clinical significance of MYCN gain as detected by FISH in neuroblastoma (Q82287350) (← links)
- Increased plasma concentration of cell-free DNA precedes disease recurrence in children with high-risk neuroblastoma (Q89579337) (← links)
- Analysis of ALK, MYCN, and the ALK ligand ALKAL2 (FAM150B/AUGα) in neuroblastoma patient samples with chromosome arm 2p rearrangements (Q92147504) (← links)